Login

Financial Snapshot

Revenue
TTM
$71.13B
Gross Margin
TTM
72.59%
Net Income
TTM
$12.23B
Current Assets
2026 Q1
$30.16B
Current Liabilities
2026 Q1
$30.01B
Current Ratio
2026 Q1
100.52%
Total Assets
2026 Q1
$128.0B
Total Liabilities
2026 Q1
$55.22B
Book Value
2026 Q1
72.81B
Cash
2026 Q1
$5.544B
P/E
TTM
7.240
Free Cash Flow
TTM
$271.0M

Stock Price

Loading...
Market Cap: $88.533 Billion

About Sanofi SA

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 76,493 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Industry: Pharmaceutical Preparations

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support